Health & Fitness
Wed, February 11, 2009Tue, February 10, 2009Mon, February 9, 2009Sun, February 8, 2009Fri, February 6, 2009Thu, February 5, 2009Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Sun, February 1, 2009Sat, January 31, 2009Fri, January 30, 2009Thu, January 29, 2009Wed, January 28, 2009Lpath, Inc.: Lpath to Provide Fourth Quarter 2008 Business Review and 2009 Plan
//health-fitness.news-articles.net/content/2009/ .. -quarter-2008-business-review-and-2009-plan.html
Published in Health and Fitness on Wednesday, February 4th 2009 at 10:01 GMT, Last Modified on 2009-02-04 10:02:37 by Market Wire🞛 This publication is a summary or evaluation of another publication
SAN DIEGO, CA--(Marketwire - February 4, 2009) - Lpath, Inc. (
Lpath's chief executive officer, Scott Pancoast, will conduct the call. There will be a question-and-answer session directly following the presentation.
To participate in the teleconference, please call toll-free 877-407-9210 (direct dial 201-689-8049) five minutes before the scheduled start in order to register for the call. The call is also accessible on the Internet at [ http://www.investorcalendar.com/IC/CEPage.asp?ID=140640 ].
A replay of the call will be available three hours after the call's completion for seven days at 877-660-6853 (direct dial 201-612-7415). Account number 286 and conference ID number 312160 are both required for playback.
About Lpath
Lpath, Inc., headquartered in San Diego, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP™, an antibody against Sphingosine-1-Phosphate (S1P), is currently in a Phase 1 clinical trial in cancer and also holds promise against multiple sclerosis and various other disorders. ASONEP is being developed with the support of partner Merck-Serono as part of a worldwide exclusive license. A second product candidate, iSONEP™ (the ocular formulation of the S1P antibody), has demonstrated superior results in various preclinical models of age-related macular degeneration (AMD) and retinopathy and is in a Phase 1 clinical trial in wet-AMD patients. Lpath's third product candidate, Lpathomab™, is an antibody against Lysophosphatidic Acid (LPA), a key bioactive lipid that has been long recognized as a valid disease target (cancer, neuropathic pain, fibrosis). The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2™ drug-discovery engine, which the company is leveraging as a means to expand its pipeline. Please visit [ www.Lpath.com ].
